Drugs / HAFNIUM OXIDE
HAFNIUM OXIDE
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04615013 | Nov 2020 → Oct 2027 expected | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03589339 | Jan 2019 → Apr 2027 expected | head and neck squamous cell carcinoma, high grade malignant neoplasm, metastatic melanoma, non-small cell lung carcinoma +5 | Nanobiotix | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07224152 | Mar 2026 → Aug 2028 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02805894 | Nov 2017 → Mar 2020 | prostate cancer | Nanobiotix | Terminated | No outcome recorded |
| Phase 1/2 | NCT02901483 | Oct 2016 → Aug 2020 | head and neck squamous cell carcinoma | PharmaEngine | Terminated | No outcome recorded |
| Phase 1/2 | NCT02465593 | Jun 2015 → Jul 2021 | rectal cancer | PharmaEngine | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAFNIUM OXIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298051 ↗ |
| Known as | NBTXR3 | “hafnium oxide-containing nanoparticles NBTXR3 (NBTXR3)” NCT04615013 ↗ |
| Known as | NSC-158931 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298051 ↗ |
| Known as | PEP503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02901483 ↗ |
| Modality | Other / unclassified | “PEP503 (NBTXR3) nanoparticles” PMID 37166053 ↗ May 2023 |
| Route | Other | “Single local administration of NBTXR3 by injection into the prostate gland” NCT02805894 ↗ |